ALCAR Stock Overview
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€11.61|
|52 Week High||€31.70|
|52 Week Low||€8.14|
|1 Month Change||13.27%|
|3 Month Change||12.72%|
|1 Year Change||-51.73%|
|3 Year Change||-45.24%|
|5 Year Change||-60.13%|
|Change since IPO||-47.47%|
Recent News & Updates
|ALCAR||FR Medical Equipment||FR Market|
Return vs Industry: ALCAR underperformed the French Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: ALCAR underperformed the French Market which returned -5.4% over the past year.
|ALCAR Average Weekly Movement||15.2%|
|Medical Equipment Industry Average Movement||7.1%|
|Market Average Movement||6.1%|
|10% most volatile stocks in FR Market||10.5%|
|10% least volatile stocks in FR Market||3.6%|
Stable Share Price: ALCAR is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ALCAR's weekly volatility has increased from 9% to 15% over the past year.
About the Company
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
Carmat Fundamentals Summary
|ALCAR fundamental statistics|
Is ALCAR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALCAR income statement (TTM)|
|Cost of Revenue||€47.79m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 15, 2022
|Earnings per share (EPS)||-3.15|
|Net Profit Margin||-2,765.89%|
How did ALCAR perform over the long term?See historical performance and comparison
Is Carmat undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALCAR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALCAR's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALCAR is unprofitable, so we can't compare its PE Ratio to the French Medical Equipment industry average.
PE vs Market: ALCAR is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALCAR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALCAR is overvalued based on its PB Ratio (237.8x) compared to the FR Medical Equipment industry average (2.2x).
How is Carmat forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALCAR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALCAR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALCAR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALCAR's revenue (50.6% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: ALCAR's revenue (50.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALCAR's Return on Equity is forecast to be high in 3 years time
How has Carmat performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCAR is currently unprofitable.
Growing Profit Margin: ALCAR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALCAR is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare ALCAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALCAR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: ALCAR has a negative Return on Equity (-6458.56%), as it is currently unprofitable.
How is Carmat's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALCAR's short term assets (€61.7M) exceed its short term liabilities (€13.9M).
Long Term Liabilities: ALCAR's short term assets (€61.7M) exceed its long term liabilities (€54.2M).
Debt to Equity History and Analysis
Debt Level: ALCAR's net debt to equity ratio (1338.9%) is considered high.
Reducing Debt: ALCAR's debt to equity ratio has increased from 11.2% to 5430% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALCAR has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ALCAR is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
What is Carmat current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCAR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCAR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALCAR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Stephane Piat (50 yo)
Mr. Stéphane Piat has been Chief Executive Officer of Carmat SA since August 29, 2016 and has been its Director since April 27, 2017. Mr. Piat is an acknowledged specialist in the medical device business,...
CEO Compensation Analysis
Compensation vs Market: Stephane's total compensation ($USD3.07M) is above average for companies of similar size in the French market ($USD385.78K).
Compensation vs Earnings: Stephane's compensation has increased whilst the company is unprofitable.
Experienced Board: ALCAR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.1%.
Carmat SA's employee growth, exchange listings and data sources
- Name: Carmat SA
- Ticker: ALCAR
- Exchange: ENXTPA
- Founded: 2008
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €227.733m
- Shares outstanding: 19.62m
- Website: https://www.carmatsa.com
Number of Employees
- Carmat SA
- 36, avenue de l'Europe
- Immeuble l'Etendard
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.